Hybridoma technology features the effective usage of innate functions of both immune and cancer cells to generate monoclonal antibodies (mAbs). The resulting hybridoma cell lines are produced to combat specific antigens of interest. Such technology has forged remarkable new approaches toward therapeutic mAb discovery, as well as disease diagnosis and prevention.
Synbio Technologies has a robust antibody drug discovery platform utilized by our talented scientific team from both local and international antibody specialists. This platform provides a full range of services in custom monoclonal antibody production including immunization, hybridoma development, antibody discovery, antibody functional screening assays, antibody engineering, and antibody expression. Using this platform, we can deliver up to 10 high-quality functional hybridoma clones to jumpstart our customers’ antibody research.
To better serve our customers, Synbio Technologies offers our high-quality, customizable “one stop solution” for antibody drug discovery. Our protocol is adjustable based on the requirements of clients or the progress of the project.
- Proprietary Immunization Technology: Compared to traditional immunogen design, our Universal AntigenTMcan induce antibodies to recognize epitopes containing less than 5 amino acids.
- One Stop Solution: Streamlined strategy from immunization to hybridoma generation and characterization.
- Reliable High-Throughput Screening Assays: Optimized immunization and high-throughput screening for affinity measurements, epitope binning, isotyping, etc.
- Comprehensive Functional Assay: Extensive experience in antibody affinity ranking, affinity measurement, cross-reactivity, and other in-vitro biological analysis.